Welcome to our dedicated page for Novonix SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NOVONIX Limited (NVNXF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. NOVONIX files Form 6-K current reports under the Securities Exchange Act of 1934, identified by Commission File Number 001-41208. These filings typically incorporate Australian Securities Exchange (ASX) documents and other materials that describe changes in NOVONIX’s securities, governance, and corporate actions.
Recent NOVONIX 6-K filings reference ASX forms such as Appendix 2A (Application for quotation of securities), Appendix 3H (Notification of cessation of securities), and Appendix 3X (Initial Director’s Interest Notice). Through these exhibits, investors can track events including new share quotations, cessation of securities, and initial disclosures of director interests. Other 6-Ks attach ASX announcements related to board appointments and other corporate developments.
For NVNXF investors, these filings complement company news releases that discuss NOVONIX’s battery materials and technology activities, including synthetic graphite projects in Chattanooga, Tennessee, technology licensing arrangements, and financing transactions. While detailed financial statements and risk discussions are typically provided in annual and periodic reports, the 6-Ks offer interim updates on material information that NOVONIX chooses to furnish to the SEC.
On this page, Stock Titan surfaces NOVONIX’s SEC submissions as they appear on EDGAR and pairs them with AI-powered summaries to explain the practical meaning of each filing. This can help readers quickly understand whether a filing relates to new securities being quoted, changes in existing securities, director interest notices, or other corporate announcements. Users interested in insider-related disclosures can review exhibits such as Appendix 3X, while those focused on capital structure can examine Appendices 2A and 3H and their associated descriptions.
Novonix Limited has filed a Form 6-K as a foreign private issuer for March 2026. The filing primarily furnishes an ASX announcement titled “Nasdaq Notice of Minimum Bid Price Deficiency” dated March 18, 2026, indicating the company is addressing a Nasdaq minimum bid price compliance matter.
Novonix Limited has called its 2026 Annual General Meeting for 15 April 2026 as a hybrid event in Brisbane and online, where shareholders can watch, ask questions and vote virtually or in person.
Key items include receiving the FY25 financial and remuneration reports, advisory approval of the 2025 Remuneration Report, and re-election of directors Admiral Robert Natter and Ronald Edmonds. Shareholders are asked to re-approve the Performance Rights Plan for up to 35,000,000 Performance Rights and to grant CEO Michael O’Kronley 5,862,567 FY26 Performance Rights tied to three-year relative TSR and a 2028 revenue modifier. Resolutions also seek approval for 1,371,566 FY26 Share Rights across Phillips 66 Company and six non-executive directors, and an additional 10% share placement capacity under ASX Listing Rule 7.1A, taking potential placement headroom to 25% if approved.
NOVONIX Ltd’s Chief Financial Officer Robert Buell Long filed an initial ownership report showing his equity-based incentives. The Form 3 lists performance rights that can convert into 1,363,398 ordinary shares expiring in 2028, 2,069,142 shares expiring in 2029, and 1,144,130 shares expiring in 2027, all with a conversion price of $0.0000.
NOVONIX Ltd reported the initial equity holdings of Chief Legal and Risk Officer Kimberly J. Heimert. The filing lists two blocks of performance rights that can convert to ordinary shares at an exercise price of
One block relates to 489,818 underlying ordinary shares with an exercise date on
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson filed an initial ownership report showing he holds several grants of performance rights linked to NOVONIX ordinary shares. These performance rights have a zero exercise price and, if vesting conditions are met, can convert into ordinary shares over multiple future dates.
The holdings include one grant tied to 1,724,285 underlying ordinary shares and another tied to 173,062 underlying shares, with exercise dates at the end of 2028 and 2027, respectively. Additional time-based performance rights cover blocks of 258,883 or 258,884 underlying ordinary shares each, with exercise dates on November 1, 2026, 2027, 2028, and 2029, and expirations generally on November 1, 2030. The filing lists these positions only and does not show any new market purchases or sales.
NOVONIX Ltd filed an initial insider ownership report for Chief Executive Officer Michael O'Kronley. The filing shows he holds performance rights that can be converted into 3,723,971 ordinary shares at an exercise price of $0.0000 per share, with these rights expiring on December 31, 2028. This is a holdings disclosure rather than a new buy or sell transaction.
NOVONIX Ltd director Robert J. Natter has filed a Form 3 reporting his existing ownership of the company’s ordinary shares. The filing shows 230,343 ordinary shares held directly. It also shows indirect ownership through trusts, with 1,365,888 ordinary shares held in a trust where he is trustee and 1,298,758 ordinary shares held in a trust where his spouse is trustee. These entries are reported as holdings, not as new market transactions, and provide a baseline view of his beneficial ownership in NOVONIX.
NOVONIX Ltd director Ronald C. Edmonds has filed an initial Form 3 disclosing his ownership in the company. The filing reports that he directly holds 416,342 ordinary shares as of March 16, 2026. This establishes his starting equity position as a reporting insider under SEC rules.
NOVONIX Ltd director files initial ownership report with no transactions
NOVONIX Ltd director Vaidyanathan Suresh has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The filing does not report any equity transactions or derivative exercises, and shows no derivative positions in the derivative summary section.
NOVONIX Ltd director Jean Oelwang filed an initial Form 3 disclosing current holdings in the company. The filing reports direct ownership of 309,508 ordinary shares of NOVONIX as of the reported date, with no associated purchase, sale, or derivative transactions described.